Vertaling van "vaccines and diagnostics is launching the new menveo " (Nederlands → Frans) :

In addition to the exceptional sales contributions from A (H1N1) pandemic vaccines, Vaccines and Diagnostics is launching the new Menveo vaccine in the US and Europe while expanding in targeted emerging markets.
Outre ses contributions provenant des ventes exceptionnelles des vaccins contre la pandémie de grippe A (H1N1), Vaccins et Diagnostic lance le nouveau vaccin Menveo aux Etats-Unis et en Europe tout en poursuivant son expansion dans des marchés émergents ciblés.

Vaccines and Diagnostics is preparing the launch of Menveo, a developmental vaccine against four serogroups of meningococcal meningitis.
Vaccins et Diagnostic se prépare à lancer Menveo, un vaccin en développement contre quatre sérogroupes de méningite à méningocoque.

Delivering innovation, growth and productivity The success of Novartis is driven by a commitment to three strategic priorities: (1) extending our lead in innovation through the research and development of differentiated new medicines, vaccines and diagnostics; (2) accelerating growth across all divisions by broadening our product portfolios with new launches and increasing our presence in new markets; and (3) improving profitability through productivity by streamlining and simplifying our processes.
Promouvoir l'innovation, la croissance et la productivité Le succès de Novartis est porté par son engagement envers trois priorités stratégiques: Augmenter notre avance dans l’innovation en recherchant et développant de nouveaux médicaments, vaccins et diagnostics différenciés, 2) accélérer notre croissance dans toutes les divisions en élargissant notre portefeuille par le lancement de nouveaux de produits et en accroissant notre présence dans de nouveaux marchés et 3) améliorer notre profitabilité par le biais de la productivité en rationalisant et en simplifiant nos processus.

Vaccines and Diagnostics: +8% to USD 78 million Higher vaccine volumes and a better product mix helped support major R&D investments in the Phase III meningitis vaccine candidates Menveo and MenB as well as initiatives to improve vaccines manufacturing quality and capacity.
Vaccins et Diagnostic: +8% à USD 78 millions Une hausse du volume des vaccins et une amélioration du mixte des produits ont contribué à soutenir des investissements importants dans les vaccins candidats contre la méningite Menveo et MenB en phase III de développement ainsi que dans des projets visant à améliorer la qualité et la capacité de la production de vaccins.

Vaccines and Diagnostics Menveo, a novel vaccine in clinical development to protect against four common types of meningococcal meningitis, is making good progress toward US and European regulatory approvals for initial use in adolescents (from age 11) and adults.
Vaccins et Diagnostic Menveo, un nouveau vaccin en développement clinique contre quatre types communs de méningite à méningocoques progresse vers l’obtention d’autorisations aux Etats-Unis et en Europe pour une première utilisation chez les adolescents (à partir de l’âge de 11) et les adultes.

Vaccines and Diagnostics began delivering vaccines in the last week of September for the new H1N1 influenza strain as US and European regulatory approvals were received.
Vaccins et Diagnostic a commencé les livraisons de vaccins dans la dernière semaine de septembre pour la nouvelle souche de virus grippal H1N1, après avoir reçu les autorisations réglementaires aux Etats-Unis et en Europe.

Vaccines and Diagnostics is making good progress in creating a vaccine against the new strain of influenza A(H1N1).
Vaccins et Diagnostic réalise une bonne progression dans la création d’un vaccin contre la nouvelle souche du virus de la grippe A(H1N1).

“Pfizer’s commitments build on our ongoing efforts to fight neglected tropical diseases, which includes the work done through our support of the International Trachoma Initiative, by our colleagues who participate in our Global Health Fellows program, and through our participation in WIPO Re: Search -- a publicprivate consortium for sharing intellectual property and expertise with the global health research community to promote the development of new drugs, vaccines and diagnostics for the treatment of neglected tropical diseases, malaria and tuberculosis. “We are proud to be a part of this innovative effort to support a healthier world”.
“Pfizer’s commitments build on our ongoing efforts to fight neglected tropical diseases, which includes the work done through our support of the International Trachoma Initiative, by our colleagues who participate in our Global Health Fellows program, and through our participation in WIPO Re: Search -- a publicprivate consortium for sharing intellectual property and expertise with the global health research community to promote the development of new drugs, vaccines and diagnostics for the treatment of neglected tropical diseases, malaria and tuberculosis.

NEW YORK , N.Y., December 12 - Pfizer Inc. announced that Prevenar 13* (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) was introduced into the first childhood immunization program for pneumococcal disease (PD) in the developing world under the auspices of the Advance Market Commitment (AMC) when Nicaragua launched its program today .
NEW YORK , N.Y., December 12 - Pfizer Inc. announced that Prevenar 13* (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) was introduced into the first childhood immunization program for pneumococcal disease (PD) in the developing world under the auspices of the Advance Market Commitment (AMC) when Nicaragua launched its program today .